Pfizer in $635 Million Deal - Analyst Blog

By
A A A

Pfizer Inc. ( PFE ) recently entered into a worldwide strategic collaboration agreement with biotech company, CytomX Therapeutics, Inc., for the development and commercialization of a new generation of targeted antibody therapeutics.

The companies will work on the development of Probody-drug conjugates (PDCs). The CytomX's Probody platform will be used for the development of safer and more effective antibody-drug conjugates (ADCs). The aim is to combine cytotoxic agents with masked Probodies that are activated only in the disease microenvironment.

Pfizer will have exclusive rights to develop and commercialize select PDCs. Both companies will conduct preclinical research together with Pfizer assuming responsibility for the development and potential commercialization of any selected PDCs.

The deal, worth $635 million, includes up-front, research reimbursement and preclinical milestone payments of about $25 million and regulatory and sales milestone payments of about $610 million to CytomX. CytomX will also receive tiered double-digit royalties on future sales.

We note that Pfizer has been pretty active on signing deals for early-stage candidates. Earlier this year, the company had announced a worldwide collaboration agreement with biopharma company BIND Therapeutics for the development and commercialization of a new class of highly selective targeted and programmable therapeutics called Accurins.

Under this deal, BIND may receive about $50 million in the form of up-front and development milestone payments and approximately $160 million on the achievement of regulatory and sales milestones along with tiered royalties on future sales.

Pfizer currently carries a Zacks Rank #3 (Hold). The company's pipeline needs to deliver given the Lipitor loss of exclusivity and the upcoming loss of exclusivity on additional products in the next few years.

At present, companies like Santarus, Inc. ( SNTS ), Jazz Pharmaceuticals ( JAZZ ) and Salix Pharmaceuticals ( SLXP ) look well-positioned with all three being Zacks Rank #1 (Strong Buy) stocks.



JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report

PFIZER INC (PFE): Free Stock Analysis Report


SALIX PHARM-LTD (SLXP): Free Stock Analysis Report

SANTARUS INC (SNTS): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.




This article appears in: Investing , Business , Stocks

Referenced Stocks: JAZZ , PFE , SLXP , SNTS

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

What to Wear to a Wedding
What to Wear to a Wedding           
4th of July Outfits
4th of July Outfits                 

Stocks

Referenced

Most Active by Volume

62,287,287
  • $17.03 ▼ 1.10%
26,194,993
  • $30.555 ▲ 1.24%
26,150,957
  • $126.44 ▼ 0.13%
25,197,634
  • $40.59 ▼ 6.26%
25,192,083
  • $19.07 ▲ 1.54%
24,563,617
  • $26.78 ▲ 0.45%
24,474,256
  • $5.85 ▲ 1.56%
24,111,132
  • $8.83 ▲ 2.08%
As of 7/2/2015, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com